Shares of Alkem Laboratories saw an uptick on February 5, 2025, following the company’s launch of its new Kojiglo serum in the Indian market. The product is designed to manage facial hyperpigmentation and is suitable for all skin types. At 09:29 am, the company's stock price was quoted at Rs 5,162.25, marking an increase of Rs 55.00, or 1.08 percent, on the BSE.
Alkem is the first Indian company to introduce a liposomal serum utilizing Duo-Lipo technology. This breakthrough formulation combines advanced ingredients such as liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide. The unique Duo-Lipo technology encapsulates these active ingredients in liposomal form, enhancing their penetration into the skin for more effective and targeted action.
In addition to the product launch, Alkem Laboratories has scheduled a board meeting on February 7, 2025, to approve its unaudited financial results for the quarter and nine months ending December 31, 2024. The board will also consider declaring an interim dividend for the 2024-2025 financial year, with February 14 set as the record date for payment, subject to approval.
